238 related articles for article (PubMed ID: 22847125)
1. Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Minato T; Yamamoto Y; Seike J; Yoshida T; Yamai H; Takechi H; Yuasa Y; Furukita Y; Goto M; Bando Y; Tangoku A
Ann Surg Oncol; 2013 Jan; 20(1):209-17. PubMed ID: 22847125
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
[TBL] [Abstract][Full Text] [Related]
3. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
4. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
[TBL] [Abstract][Full Text] [Related]
5. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cell marker ALDH1 expression is associated with lymph node metastasis and poor survival in esophageal squamous cell carcinoma: a study from high incidence area of northern China.
Wang Y; Zhe H; Gao P; Zhang N; Li G; Qin J
Dis Esophagus; 2012 Aug; 25(6):560-5. PubMed ID: 22098156
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Lyu X; Huang J; Mao Y; Liu Y; Feng Q; Shao K; Gao S; Jiang Y; Wang J; He J
J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
[TBL] [Abstract][Full Text] [Related]
10. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Nomura M; Oze I; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Kawai R; Uemura N; Ishihara M; Tanaka T; Tajika M; Niwa Y; Muro K; Muto M
Cancer Chemother Pharmacol; 2015 Aug; 76(2):357-63. PubMed ID: 26092324
[TBL] [Abstract][Full Text] [Related]
11. Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications.
Rahadiani N; Ikeda J; Mamat S; Matsuzaki S; Ueda Y; Umehara R; Tian T; Wang Y; Enomoto T; Kimura T; Aozasa K; Morii E
Cancer Sci; 2011 Apr; 102(4):903-8. PubMed ID: 21231983
[TBL] [Abstract][Full Text] [Related]
12. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
Alamgeer M; Ganju V; Kumar B; Fox J; Hart S; White M; Harris M; Stuckey J; Prodanovic Z; Schneider-Kolsky ME; Watkins DN
Breast Cancer Res; 2014 Apr; 16(2):R44. PubMed ID: 24762066
[TBL] [Abstract][Full Text] [Related]
13. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
[TBL] [Abstract][Full Text] [Related]
16. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]